<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19251">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856269</url>
  </required_header>
  <id_info>
    <org_study_id>02-15-07</org_study_id>
    <nct_id>NCT02856269</nct_id>
  </id_info>
  <brief_title>Zinc Supplementation and Cardiovascular Risk in HIV</brief_title>
  <official_title>Zinc Supplementation and Cardiovascular Risk in HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grace McComsey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine whether zinc supplementation significantly
      affects immune activation in HIV-infected subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Zinc Level</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>45 mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will take a daily 45 mg dose of zinc gluconate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will take a daily 90 mg dose of zinc gluconate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc gluconate</intervention_name>
    <description>Participants will take a daily dose of zinc gluconate.</description>
    <arm_group_label>45 mg daily</arm_group_label>
    <arm_group_label>90 mg daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  Age ≥18 years

          -  Zinc level ≤0.75 mg/L

          -  Receiving a stable antiretroviral regimen with no plans to change during study

          -  Documentation of an HIV-1 RNA level of ≤400 copies/mL

          -  No diarrhea or nausea/vomiting for the last month

        Exclusion Criteria:

          -  Pregnancy/lactation

          -  Presence of inflammatory condition

          -  Regular use of agents that may affect inflammation in the last 3 months. The regular
             use of NSAIDS, aspirin, or statins will be allowed as long as dose has been stable
             for the last 3 months and is not expected to change during the study.

          -  Presence of active neoplastic diseases requiring chemotherapy and/or use of
             immunosuppressive drugs

          -  Known cardiovascular disease

          -  Uncontrolled diabetes

          -  Allergy or intolerance to zinc sulfate.

          -  AST and ALT &gt; 2.5 x ULN

          -  Hemoglobin &lt; 9.0 g/dL

          -  GFR &lt;50 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace McComsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grace McComsey, MD</last_name>
    <phone>216-844-2739</phone>
    <email>mccomsey.grace@clevelandactu.org</email>
  </overall_contact>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 13, 2016</lastchanged_date>
  <firstreceived_date>July 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Case Medical Center</investigator_affiliation>
    <investigator_full_name>Grace McComsey</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Zinc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
